Abstract
Background: Despite advances in behavioral and pharmacotherapy interventions, substance use disorders (SUDs) are frequently refractory to treatment. Glutamatergic dysregulation has received increasing attention as one common neuropathology across multiple substances of abuse. Ketamine is a potent N-methyl-D-aspartate (NMDA) glutamatergic receptor antagonist which has been found to be effective in the treatment of severe depression. Here we review the literature on the efficacy of ketamine in the treatment of SUDs. Methods: A systematic review of the PubMed, Scopus, and ClinicalTrials.gov databases was undertaken to identify completed and ongoing human studies of the effectiveness of ketamine in the treatment of SUDs between January 1997 and January 2018. Results and conclusion: Seven completed studies were identified. Two studies focused on alcohol use disorder, two focused on cocaine use disorder, and three focused on opioid use disorder. Both cocaine studies found improvements in craving, motivation, and decreased cocaine use rates, although studies were limited by small sample sizes, a homogeneous population and short follow-up. Studies of alcohol and opioid use disorders found improvement in abstinence rates in the ketamine...Continue Reading
References
Apr 1, 1997·Journal of Psychoactive Drugs·E M Krupitsky, A Y Grinenko
Oct 4, 2000·JAMA : the Journal of the American Medical Association·A T McLellanH D Kleber
Dec 24, 2002·Journal of Substance Abuse Treatment·Evgeny KrupitskyAlexander Grinenko
May 26, 2007·Journal of Psychoactive Drugs·Evgeny M KrupitskyAlexander Y Grinenko
Aug 21, 2007·Biochemical Pharmacology·Justin T Gass, M Foster Olive
Jul 25, 2012·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Ronald S Duman, Nanxin Li
Sep 3, 2013·Lancet·Harvey A WhitefordTheo Vos
Sep 17, 2013·Biological Psychiatry·Elias DakwarCarl L Hart
Jan 7, 2014·Journal of Affective Disorders·Marie NaughtonTimothy G Dinan
Feb 13, 2014·PloS One·Marilyn D SkinnerHenri-Jean Aubin
May 16, 2014·JAMA : the Journal of the American Medical Association·Daniel E JonasJames C Garbutt
Aug 16, 2014·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Caitlin NotleyRichard Holland
Oct 18, 2014·The Annals of Pharmacotherapy·Adrian WongSandra L Kane-Gill
Dec 30, 2014·The International Journal of Neuropsychopharmacology·Mark J NiciuCarlos A Zarate
Jan 12, 2016·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Matthew D CooperRoger S McIntyre
Apr 20, 2016·Molecular Psychiatry·E DakwarR W Foltin
Nov 12, 2016·BMC Psychiatry·Laurence LalanneEric Salvat
Nov 16, 2016·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Karl MannWim van den Brink
Nov 16, 2016·Neuropsychiatric Disease and Treatment·Yu HanPeng Xie
Jan 24, 2017·Journal of Clinical Pharmacy and Therapeutics·S E StrasburgerR B Raffa
Mar 18, 2017·Nature Reviews. Drug Discovery·James W MurroughSanjay J Mathew
Mar 28, 2017·Neuroscience and Biobehavioral Reviews·Francesco BartoliGiuseppe Carrà
Oct 17, 2017·Biological Psychiatry : Cognitive Neuroscience and Neuroimaging·Chadi G AbdallahDaniel H Mathalon
Oct 19, 2017·A & a Case Reports·Elise M StricklerEugene R Viscusi
Jan 9, 2018·Neuropharmacology·E DakwarF R Levin
Jan 19, 2018·The Journal of Clinical Psychiatry·Francesco BartoliGiuseppe Carrà
Citations
Jun 20, 2019·Psychiatry and Clinical Neurosciences·Kenji Hashimoto
Jan 7, 2020·Journal of Palliative Medicine·April Christensen, Jennifer Pruskowski
Sep 6, 2020·Addiction·Laura BrandtFrances R Levin
Jun 11, 2019·Frontiers in Psychiatry·Marianne DestoopGeert Dom
Jun 9, 2020·Frontiers in Behavioral Neuroscience·Greer McKendrickNicholas M Graziane
May 17, 2019·Oxidative Medicine and Cellular Longevity·Christonikos LeventelisDemetrios Kouretas
Dec 15, 2020·Journal of Psychopharmacology·Rebecca L RothbergElias Dakwar
Jul 28, 2019·European Journal of Pharmacology·Agata Nowacka, Malgorzata Borczyk
Feb 12, 2021·International Review of Psychiatry·Luke A Jelen, James M Stone
Feb 13, 2021·Pharmacology, Biochemistry, and Behavior·Hana ShafiquePiotr Popik
Feb 21, 2021·Pharmacological Reports : PR·Samuel Kohtala
Feb 18, 2020·Behavioural Brain Research·Saurabh S KokaneLinda I Perrotti
Apr 3, 2020·Journal of the Neurological Sciences·Molly C KalmoeCharles R Conway
Apr 3, 2020·The Journal of Emergency Medicine·Reuben J StrayerLewis S Nelson
Apr 1, 2021·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Jana Ruda-KucerovaYousef Tizabi
Aug 8, 2020·Pharmacology, Biochemistry, and Behavior·Piotr PopikJeffrey M Witkin
May 18, 2021·Frontiers in Neuroscience·Ezio CarboniAntonello Novelli
Jun 8, 2021·Journal of Psychopharmacology·John Martin CorkeryFabrizio Schifano
Jul 3, 2021·Brain Sciences·Giovanni MartinottiMassimo Di Giannantonio
Jun 29, 2021·Expert Opinion on Drug Safety·Jan Van Amsterdam, Wim Van Den Brink
Jul 20, 2020·Current Drug Targets·Mohammad Farris Iman Leong Bin Abdullah
Sep 7, 2021·Frontiers in Psychiatry·O Merve MollaahmetogluCelia J A Morgan